Assessing treatment efficacy and early infant diagnosis (EID) are critical issues in HIV disease management. Point-of-care assays may greatly increase the possibility to access laboratory monitoring also in rural areas. Recently two new laboratory tests have been developed by Cepheid (Sunnyvale, California) the Xpert HIV-1 Viral Load for viral load determination and the Xpert HIV-1 Qualitative for early infant diagnosis. We conducted a study in Blantyre, Malawi, comparing the 2 methods versus the Abbott real time quantitative and qualitative assays, for viral load and EID respectively. We tested 300 plasma samples for viral load determination and 200 samples for infant diagnosis. HIV-1 RNA values of the 274 samples quantified by both assays were highly correlated (Pearson r=0.95, R(2)=0.90). In 90.9% of the cases the two methods were concordant in defining the HIV-1 RNA levels as detectable or undetectable. For EID, the Xpert HIV-1 Qualitative assay yielded the same identical results as the Abbott assay. Both the quantitative and the qualitative Xpert assays are promising tools to monitor treatment efficacy in HIV patients receiving treatment and for early diagnosis in HIV-exposed infants.

Ceffa, S., Luhanga, R., Andreotti, M., Brambilla, D., Erba, F., Jere, H., et al. (2016). Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. JOURNAL OF VIROLOGICAL METHODS, 229, 35-39 [10.1016/j.jviromet.2015.12.007].

Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection

ERBA, FULVIO;MANCINELLI, SANDRO;PALOMBI, LEONARDO;
2016-01-01

Abstract

Assessing treatment efficacy and early infant diagnosis (EID) are critical issues in HIV disease management. Point-of-care assays may greatly increase the possibility to access laboratory monitoring also in rural areas. Recently two new laboratory tests have been developed by Cepheid (Sunnyvale, California) the Xpert HIV-1 Viral Load for viral load determination and the Xpert HIV-1 Qualitative for early infant diagnosis. We conducted a study in Blantyre, Malawi, comparing the 2 methods versus the Abbott real time quantitative and qualitative assays, for viral load and EID respectively. We tested 300 plasma samples for viral load determination and 200 samples for infant diagnosis. HIV-1 RNA values of the 274 samples quantified by both assays were highly correlated (Pearson r=0.95, R(2)=0.90). In 90.9% of the cases the two methods were concordant in defining the HIV-1 RNA levels as detectable or undetectable. For EID, the Xpert HIV-1 Qualitative assay yielded the same identical results as the Abbott assay. Both the quantitative and the qualitative Xpert assays are promising tools to monitor treatment efficacy in HIV patients receiving treatment and for early diagnosis in HIV-exposed infants.
2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/42 - IGIENE GENERALE E APPLICATA
English
Con Impact Factor ISI
Early infant diagnosis; HIV-1; POC tests; Viral load
Epub 2015 Dec 17.
http://www.sciencedirect.com/science/article/pii/S0166093415300239
Ceffa, S., Luhanga, R., Andreotti, M., Brambilla, D., Erba, F., Jere, H., et al. (2016). Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. JOURNAL OF VIROLOGICAL METHODS, 229, 35-39 [10.1016/j.jviromet.2015.12.007].
Ceffa, S; Luhanga, R; Andreotti, M; Brambilla, D; Erba, F; Jere, H; Mancinelli, S; Giuliano, M; Palombi, L; Marazzi, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Comparison of the Cepheid GeneXpert and Abbott M2000.pdf

solo utenti autorizzati

Licenza: Non specificato
Dimensione 459.31 kB
Formato Adobe PDF
459.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/172629
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 53
social impact